The May 31, 2012, QuarterWatch, Monitoring FDA MedWatch Reports, released by the ISMP (Institute for Safe Medication Practices) has confirmed that PRADAXA (DABIGATRAN ETEXILATE) lead all drugs in adverse event reports in 2011 with a total of 3,781 serious adverse events reported by both the manufacturer and direct reports. More information appears here at PRADAXA CASES.